Jazz Pharmaceuticals plc (NASDAQ:JAZZ – Get Rating) SVP Samantha Pearce sold 8,508 shares of the business’s stock in a transaction that occurred on Monday, June 27th. The shares were sold at an average price of $155.00, for a total transaction of $1,318,740.00. Following the completion of the sale, the senior vice president now directly owns 11,309 shares in the company, valued at $1,752,895. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website.
Samantha Pearce also recently made the following trade(s):
On Wednesday, June 8th, Samantha Pearce sold 8,487 shares of Jazz Pharmaceuticals stock. The stock was sold at an average price of $155.00, for a total transaction of $1,315,485.00.
Jazz Pharmaceuticals stock traded up $1.12 during mid-day trading on Wednesday, reaching $156.36. The company’s stock had a trading volume of 274,444 shares, compared to its average volume of 592,861. Jazz Pharmaceuticals plc has a twelve month low of $117.64 and a twelve month high of $186.22. The firm has a market cap of $9.76 billion, a price-to-earnings ratio of -20.82, a PEG ratio of 1.27 and a beta of 0.80. The company has a current ratio of 3.39, a quick ratio of 2.06 and a debt-to-equity ratio of 1.66. The business has a 50 day moving average price of $151.29 and a 200-day moving average price of $147.06.
Jazz Pharmaceuticals (NASDAQ:JAZZ – Get Rating) last issued its quarterly earnings results on Wednesday, May 4th. The specialty pharmaceutical company reported $3.13 EPS for the quarter, topping the consensus estimate of $3.00 by $0.13. The firm had revenue of $813.72 million for the quarter, compared to analysts’ expectations of $853.73 million. Jazz Pharmaceuticals had a negative net margin of 13.63% and a positive return on equity of 22.45%. Jazz Pharmaceuticals’s revenue for the quarter was up 33.9% compared to the same quarter last year. During the same period in the previous year, the business earned $3.42 earnings per share. On average, equities analysts expect that Jazz Pharmaceuticals plc will post 14.73 EPS for the current fiscal year.
Several equities research analysts recently weighed in on JAZZ shares. UBS Group started coverage on shares of Jazz Pharmaceuticals in a research note on Monday, June 13th. They set a “buy” rating and a $194.00 target price on the stock. Piper Sandler cut their target price on shares of Jazz Pharmaceuticals from $197.00 to $193.00 in a research note on Thursday, May 5th. Cowen upped their target price on shares of Jazz Pharmaceuticals from $200.00 to $225.00 in a research note on Thursday, May 5th. Royal Bank of Canada cut their target price on shares of Jazz Pharmaceuticals from $216.00 to $214.00 and set an “outperform” rating on the stock in a research note on Wednesday, March 2nd. Finally, HC Wainwright boosted their price target on shares of Jazz Pharmaceuticals from $210.00 to $215.00 and gave the stock a “buy” rating in a report on Thursday, March 3rd. Three equities research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $204.14.
A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Private Capital Group LLC grew its stake in Jazz Pharmaceuticals by 1,975.0% during the 1st quarter. Private Capital Group LLC now owns 166 shares of the specialty pharmaceutical company’s stock valued at $26,000 after acquiring an additional 158 shares in the last quarter. Lloyd Advisory Services LLC. bought a new stake in shares of Jazz Pharmaceuticals in the 1st quarter valued at approximately $29,000. Quent Capital LLC bought a new stake in shares of Jazz Pharmaceuticals in the 4th quarter valued at approximately $31,000. National Bank of Canada FI bought a new stake in shares of Jazz Pharmaceuticals in the 4th quarter valued at approximately $35,000. Finally, Elequin Capital LP bought a new stake in shares of Jazz Pharmaceuticals in the 1st quarter valued at approximately $42,000. Hedge funds and other institutional investors own 93.23% of the company’s stock.
About Jazz Pharmaceuticals (Get Rating)
Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for various unmet medical needs in the United States, Europe, and internationally. The company has a portfolio of products and product candidates with a focus in the areas of neuroscience, including sleep medicine and movement disorders; and in oncology, including hematologic and solid tumors.